Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients

Journal of Infection

Volumn 47, Issue 1, 2003, Pages 65-72

  Gençer, Serap ^a   Salepçi, Taflan ^b   Özer, Serdar ^a  

^a Research Hospital   (Turkey)

^b Department of Internal Medicine   (Turkey)

Author keywords

Bacteria; Cancer; Febrile neutropenia; Infection; Risk factors

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; FLUCONAZOLE; IMIPENEM; MEROPENEM; NYSTATIN; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; BLOOD CULTURE; CANCER PATIENT; CANDIDIASIS; CLINICAL FEATURE; CONTROLLED STUDY; ESCHERICHIA COLI; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HYPOTENSION; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORTALITY; MUCOSA INFLAMMATION; PATHOGENICITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SHOCK; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

EID: 0037481760     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(03)00044-6     Document Type: Article

References (32)

1. Hathom JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clin Infect Dis 1997;24(Suppl 2):S256-S265.
2. Freifeld AG, Walsh TJ, Pizzo PA. Infections in the cancer patient. In: De Vita Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven; 1997. p. 2659-2704.
3. Donowitz GR. Fever in the compromised host. Infect Dis Clin North Am 1996;10:129-148.
4. Chanock SJ, Pizzo PA. Fever in the neutropenic host. Infect Dis Clin North Am 1996;10:777-795.
5. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328: 1323-1332.
6. De Pauw BE, Donnelly JP. Infections in the immunocompromised host: general principles. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases, 5th edn. Philadelphia: Churchill Livingstone; 2000. p. 3079-3090.
7. Kibler CC, Prentice HG. Pathogen 'shift' in febrile neutropenia. Curr Opin Infect Dis 1999;12:351-354.
8. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
9. Akova M. Etiology of bacterial infections in cancer patients in Europe: an ever changing scenario (12th ECCMID, Milan-Italy, 21-24 April Abstract no: S344). Clin Microbiol Infect 2002; 8(Suppl 1):50.
10. Rolston KVI, Tarrand JJ. Pseudomonas aeruginosa-still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 1999; 29:463-464.
11. Viscoli C. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998;102:879-888.
12. Aquino VM, Pappo A, Buchanan GR, et al. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 1995;14:140-143.
13. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893-900.
14. Karthaus M, Carratal J, Jürgens H, Ganser A. New strategies in the treatment of infectious complications in haematotogy and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Chemotherapy 1998;44: 424-435.
15. Rolston KVI, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996;10:223-237.
16. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18: 1012-1019.
17. Bergen GA, Shelhamer JH. Pulmonary infiltrates in the cancer patient. Infect Dis Clin North Am 1996;10:297-325.
18. Chanock SJ, Pizzo PA. Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Semin Oncol 1997;24:132-140.
19. Collin BA, Ramphal R. Pneumonia in the compromised host including cancer patients and transplant patients. Infect Dis Clin North Am 1998;12:781-805.
20. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol 2000;27: 335-346.
21. Akova M, Akan H, Korten V, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective multicentre trial in patients without previous prophylactic antibiotics. Int J Antimicrob Agents 1999;13:15-19.
22. Erman M, Akova M, Akan H, et al. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomised, multicenter study. Scand J Infect Dis 2001;33:827-831.
23. De Pauw BE, Raemarkers JM, Schattenberg T, et al. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. J Intern Med 1997;740(Suppl): 69-77.
24. Bodey GP, Buckley M, Sathe YS, et al. Quantitive relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64: 328-340.
25. Pizzo PA, Robichaud KJ, Wesley R, et al. Fever in pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-165.
26. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;48:2561-2568.
27. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
28. Çelebi H, Akan H, Akçaǧlayan E, Üstün C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant 2000;26: 211-214.
29. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18: 3038-3051.
30. Seropian S, Nadkami R, Jillella AP, et al. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant 1999;23:599-605.
31. Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis 1995;21:114-121.
32. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenic. Clin Infect Dis 1994;18:589-595.